GMDA News and Press, Gamida Cell Ltd. From 11/13/22

Gamida Cell ( NASDAQ: GMDA ) is scheduled to announce Q3 earnings results on Sunday, November 13th, before market open. The consensus EPS Estimate is -$0.31 (+6.1% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights a...

Gamida Cell ( NASDAQ: GMDA ) on Monday announced positive data from  its cell therapy candidate, GDA-501, to treat cancer. ( GMDA ) has risen ~5.4% before the bell. GDA-501, with NAM technology has shown successful expansion of natural killer cells, en...

Preclinical data presented at Society of Immunotherapy of Cancer’s 37 th Annual Meeting shows proprietary NAM technology expands NK cells, enhances functionality, increases antitumor activity, and improves homing to targeted cancer cells Data demonstrates that genet...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, ...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematological and solid cancers and other serious diseases, today announced an oral presentation of a real-world analysis comparing the effectiveness of omidubicel...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that Michele Korfin, Chief Operating Officer and Chief Commercial Officer, will present its cor...

Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...

Israel-based biotech Gamida Cell Ltd. ( NASDAQ: GMDA ) announced Thursday that its stem cell therapy candidate omidubicel led to clinical benefit at three years in a group of patients with blood cancer who typically have a poor prognosis. The analysis included long-term fo...

At three years, new data showed overall survival and disease-free survival of 63% and 56% respectively At ten years, follow-up data demonstrated sustained long-term bone marrow recovery Omidubicel patients reported clinically meaningful health-related quality of life s...